Albert J. Oosting

Hoofddorp, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Successful dose reduction of dupilumab in pediatric patients with atopic dermatitis in daily practice: results from the BioDay registry.

Successful dose reduction of dupilumab in pediatric patients with atopic dermatitis in daily practice: results from the BioDay registry.

Journal: Expert opinion on biological therapy

Published: July 13, 2026

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay.

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: January 15, 2026

Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry.

Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry.

Journal: Allergy

Published: July 29, 2025

Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results.

Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: December 19, 2024

Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.

Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.

Journal: JAMA dermatology

Published: August 07, 2024

Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels.

Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels.

Journal: Allergy

Published: March 08, 2024

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.

Journal: Journal of the American Academy of Dermatology

Published: July 26, 2023

Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry.

Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry.

Journal: The British journal of dermatology

Published: December 19, 2022

Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.

Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.

Journal: JAMA dermatology

Published: August 10, 2022

Efficacy, cost-minimization, and budget impact of a personalized discharge letter for basal cell carcinoma patients to reduce low-value follow-up care.

Efficacy, cost-minimization, and budget impact of a personalized discharge letter for basal cell carcinoma patients to reduce low-value follow-up care.

Journal: PloS one

Published: July 28, 2021

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.

Journal: Journal of the American Academy of Dermatology

Published: April 04, 2020

Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.

Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.

Journal: Allergy

Published: February 10, 2020

Showing 1-12 of 12

Last Updated: 09/26/2026